Table 3 Adverse events (safety profiles) including hematologic and non-hematologic, reported for each agent in 22 studies.

From: Comprehensive assessment of adverse event profiles associated with bispecific antibodies in multiple myeloma

Abbreviatione

Tec

TecU1

TecU2

TecJph2

Tecout

Elr

ElrP2B

F

R5458U2

AMG4

AMG7

CC

Aln

ABBV

RE5458

Tec+Tal

Tec+TalU

TalIV

Tal_0.4

Cevo

Tal+Dara

Tal+pomc

Total N

165

22

15

26

11

123

29

22

104

42

75

19

47

124

68

63

94

102

143

160

65

35

Targetf

BC

BC

BC

BC

BC

BC

BC

BC

BC

BC

BC

BC

BC

BC

BC

BGC

BGC

GC

GC

FC

GCD

GCP

Neutropenia

117

8

 

19

4

60

 

12

30

 

17

10

16

46

11

48

69

48

40

29

25

21

Anemia

86

2

 

7

 

60

 

7

44

 

32

8

16

36

 

38

53

59

38

51

34

9

Lymphopenia

57

21

 

8

2

33

 

15

18

    

19

   

53

15

   

Leukopenia

29

8

     

11

         

38

17

   

Thrombocytopenia

66

7

   

38

 

4

20

 

15

4

 

29

  

40

36

30

  

7

Neutropenia G3/4

106

8

 

19

4

60

 

9

28

  

10

14

42

9

47

64

27

37

26

17

17

Anemia G3/4

61

2

 

6

 

46

 

1

39

  

8

8

20

 

27

36

34

21

35

 

9

Lymphopenia G3/4

54

21

 

8

 

31

 

13

18

    

16

   

48

13

   

Leukopenia G3/4

12

8

     

10

         

16

14

   

Thrombocytopenia G3/4

35

7

   

29

 

2

16

 

1

4

 

15

  

28

13

21

  

7

CRSa

119

9

7

21

0

71

14

16

57

16

46

17

25

71

26

51

74

50

57

128

51

26

ICANSb

5

5

 

0

0

4

      

1

  

1

3

6

2

21

3

2

Infections

126

  

20

4

86

18

  

14

13

5

 

51

  

84

12

59

68

41

25

Hypogammaglobulinemia

123

  

15

    

9

    

17

    

15

 

55

 

Neurotoxicity

24

 

2

2

 

21

                

Neurotoxicity G3/4

1

  

0

          

0

 

1

     

Hypogammaglobulinemia G3/4

3

  

1

    

0

        

3

    

CRS G3/4

1

  

0

0

0

0

0

2

1

3

1

0

3

0

2

2

05

1

2

0

1

ICANS G3/4

0

2

 

0

0

0

          

1

 

0

1

0

0

Infections G3/4

74

  

5

 

49

11d

  

8

 

5

 

26

  

60

10

20

30

16

8

  1. Full datasets can be found in Supplementary Materials.
  2. aCytokine release syndrome.
  3. bImmune effector cell-associated neurotoxicity syndrome.
  4. cMultiple cohorts combined together.
  5. dBased on total patients of the study.
  6. eAgents abbreviation: Teclistimab: Tec, TecU1, TecU2, TecJPh2, Tecout ; Elranatamab: Elr, ElrP2B; F182112: F; Linvoseltamab (REGN-5458): RE5458, R5458U2; AMG420: AMG4; AMG701: AMG7; CC-93269 (Alnuctamab):CC, Aln; ABBV-383 (TNB-383B): ABBV; Teclistamab + Talquetamab: Tec + Tal, Tec + TalU ; Talquetamab : TalIV, Tal_0.4; Cevostamab: Cevo; Talquetamab + daratumumab: Tal + Dara ; Talquetamab + Pomalidomide: Tal + Pom.
  7. fTargets: BC: BCMA, BGC: BCMA× GPRC5D×CD3, GC: GPRC5D×CD3, FC: FcRH5×CD3, GCD: GPRC5D×CD3×Daratumumab, GCP: GPRC5D×CD3× Pomalidomide.
Back to article page